Brian Burgess, PhD
Gynecologic Oncology · Pinehurst, NCNPI 1881039121
Payments from drug & device makers
What this record shows
16 manufacturers reported payments, led by GSK at 54.2% of the total. Reporting peaked in 2023 at $2,760 and has fallen 73.5% since, to $730 in 2025.
Across 111 payments — averaging $45.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$529
- Eisai Inc.$393
- Merck$379
- Genmab U.S., Inc.$256
- Smith+Nephew$203
- plus $566 from 10 others
What the payments were for
- Consulting fees$2,17543%
- Food & beverage$2,90157%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $2,750 |
| AstraZeneca | 20 | $529 |
| Eisai Inc. | 14 | $393 |
| Merck | 16 | $379 |
| Genmab U.S., Inc. | 9 | $256 |
| Smith+Nephew | 5 | $203 |
| Astellas Pharma US Inc | 7 | $140 |
| Clovis Oncology, Inc. | 7 | $97 |
| AbbVie | 4 | $92 |
| Intuitive Surgical | 3 | $71 |
| Daiichi Sankyo Inc. | 2 | $58 |
| Johnson & Johnson | 1 | $33 |
| Immunogen, Inc. | 1 | $29 |
| Novartis | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,076 in reported general payments places this provider in the 70th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 11 | $178,652 |
| EliquisApixaban | 47 | $27,889 |
| MirenaLevonorgestrel | 11 | $12,461 |
| Fentanyl | 12 | $1,278 |
| Megestrol Acetate | 14 | $927 |
| Clobetasol Propionate | 12 | $496 |
| Gabapentin | 46 | $471 |
| Ondansetron Hcl | 101 | $422 |
| Prochlorperazine Maleate | 48 | $396 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 25 | $331 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 45 | $278 |
| Potassium Chloride | 43 | $256 |
| Dexamethasone | 52 | $246 |
| Fluconazole | 28 | $147 |
| Ibuprofen | 27 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $529 | $178,65211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 52 gynecologic oncology providers in North Carolina.
Other gynecologic oncology in Pinehurst
- Lucybeth Nieves ArribaWilmington$251K
- Robert NaumannCharlotte$221K
- Angeles SecordDurham$121K
- Erin CraneCharlotte$98K
- Michael SundborgSouthern Pines$85K
- William LoweryDurham$67K
- Emma RossiGreensboro$62K
- Jubilee BrownCharlotte$44K
- Victoria Bae-JumpChapel Hill$19K
- Andrew BerchuckDurham$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.